Journal: medRxiv
Article Title: Germline and Somatic Mutations in DNA Methyltransferase 3A (DNMT3A) Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: Implications for Associated PAH
doi: 10.1101/2023.12.30.23300391
Figure Lengend Snippet: A) Hematopoietic Dnmt3a -knockout mice spontaneously develop PAH by 9 months of age (n=4-5/group). Right ventricular systolic pressure (RVSP; in mmHg) and mean pulmonary arterial pressure (mPAP; in mmHg) are significantly increased in Dnmt3a -knockout mice (green) compared to controls (white; p=0.0004, p=0.0004, respectively). Pulmonary artery acceleration time (PAAT; in ms), tricuspid annular plane systolic excursion (TAPSE; in mm) and cardiac output (CO; in ul/min) are significantly reduced in Dnmt3a -knockout mice compared to controls (p=0.0003, p=0.012; p=0.006, respectively). Right, ventricular end-diastolic pressure (RVEDP; in mmHg) shows a trend towards being increased in Dnmt3a -knockout mice, though not statistically significant. Right-heart catheterization (RHC) traces of RVSP are shown on the left for both control (top) and knockout (bottom) mice. RVSP, mPAP, and RVEDP were obtained via RHC, while PAAT, TAPSE and CO were obtained via echocardiography. B) Hematopoietic Dnmt3a -knockout mice develop PAH, accelerated by a second hit hypoxia (n=6-9/group). 3-month-old control (white boxes) and Dnmt3a -knockout (orange boxes) mice were either maintained in normoxic (solid colour boxes) conditions for 6 weeks or were exposed to 3 weeks of hypoxia followed by 3 weeks of normoxia (boxes with bricks). Representative RVSP traces obtained via RHC are shown for each group. RVSP, mPAP and RVEDP (trending) are elevated in Dnmt3a -knockout mice that underwent a second hit (hypoxia) compared to hypoxic controls (p=0.0004, p=0.0007, p=0.0724, respectively), and RVSP, mPAP and RVEDP are also significantly increased in Dnmt3a -knockout mice that were kept in normoxia compared to the normoxic controls (p=0.0015, p=0.0015, p=0.0234, respectively). PAAT and TAPSE are significantly reduced in Dnmt3a -knockout mice that underwent a second hit (hypoxia) compared to controls (p=0.0020, p=0.0222, respectively) and are also significantly increased in Dnmt3a -knockout mice that were kept in normoxia, compared to the normoxic controls (PAAT: p=0.0030; TAPSE: p=0.0001). CO was significantly reduced in hypoxic Dnmt3a -knockout mice compared to controls (p=0.0101), while normoxic Dnmt3a -knockout mice showed a trend towards being reduced, though not statistically significant (p=0.2061). * = p< 0.05. Treatment of hypoxic Dnmt3a -knockout mice with Canakinumab (yellow bars with bricks) improved hemodynamic measurements and cardiac function (n=3; RVSP: p=0.0362, mPAP: p=0.0449, PAAT: p=0.0258, TAPSE: p=0.0533, CO: p=0.0299). RVEDP was not significantly reduced (p=0.4629).
Article Snippet: We produced male and female conditional hematopoietic Dnmt3a knockout mice by crossing parental floxed and Vav-iCre mice as described by the Jackson Laboratory ( https://www.jax.org/strain/008610 ) and by Joseph et al. 3334 This knockout simulates the ‘loss of function’ effects of DNMT3A somatic mutations seen in patients with PAH in our U.S. PAH Biobank data.
Techniques: Knock-Out